A b s t r a c t
ZAP-70 is a tyrosine kinase expressed in normal T cells and NK cells. Expression of ZAP-70 has been associated with poor prognosis in B-cell chronic lymphocytic leukemia and might be a surrogate marker for immunoglobulin heavy chain (IGH) mutational status in that disease. Little is known about ZAP-70 expression in other hematologic malignant neoplasms. We examined 446 specimens representing a range of hematopoietic malignant neoplasms for ZAP-70 expression by immunohistochemical analysis. As expected, most T cell-lineage disorders and a subset of small lymphocytic lymphomas were positive. IGH mutational status corresponded to ZAP-70 expression in a small subset of small lymphocytic lymphoma cases subjected to sequence analysis. Of note, however, ZAP-70 was expressed in a minority of other types of B-cell lymphomas, including precursor B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, and very rare cases of classic Hodgkin lymphoma. Immunohistochemical analysis represents an alternative method for assessing ZAP-70 expression and reveals that other B-cell malignant neoplasms express ZAP-70.
ZAP-70 is a Syk family protein tyrosine kinase involved in proximal T-cell receptor (TCR) signaling. 1 Activation of the TCR through antigen binding results in tyrosine phosphorylation of src-family protein tyrosine kinases such as Lck that, in turn, phosphorylate TCR-associated ZAP-70. 2, 3 Phosphorylation of ZAP-70 results in activation of the ZAP-70 tyrosine kinase activity. Phosphorylation of LAT (linker of activated T cells) by ZAP-70 serves to amplify the TCR signal and is critical in activating distal signaling pathways involving Ras and phospholipase C. [4] [5] [6] [7] Its importance in T-cell signaling and development is illustrated by the discovery of ZAP-70 mutations as a cause for a form of severe combined immunodeficiency. 8, 9 ZAP-70 is normally expressed in T cells and NK cells and once was thought to be exclusive to these lineages. Recently, ZAP-70 has been shown to be expressed during B-cell development in animal models, where it appears to be involved in the maturation of pro-B to pre-B cells within the bone marrow compartment. 10 Interest in ZAP-70 has grown since it has been shown, through gene expression profiling, that it is expressed in a subset of cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and identifies cases with unmutated immunoglobulin heavy chain (IGH) genes and relatively poor prognosis. 11, 12 However, little is known about its expression in other lymphoma types or acute leukemias. Therefore, we evaluated a series of 446 cases of classic Hodgkin lymphoma, non-Hodgkin lymphoma, and acute leukemia for expression of ZAP-70 by immunohistochemical analysis using tissue microarrays (TMAs) and whole tissue sections in selected cases.
Materials and Methods

Western Blot Analysis
Whole cell lysates were prepared from a Jurkat T-cell line known to express ZAP-70 by lysing a cell pellet in icecold lysis buffer (a 50-mmol/L concentration of tris(hydroxymethyl)aminomethane hydrochloride [pH7.2], a 150-mmol/L concentration of sodium chloride, a 10-mmol/L concentration of sodium fluoride, 0.5% deoxycholate, a 10-mmol/L concentration of EDTA, 0.1% sodium dodecyl sulfate, 1% Nonidet P-40, all from Sigma, St Louis, MO). Intact nuclei were removed by centrifugation, and the resulting cytoplasmic extract was resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA). Membranes were probed with antibodies to ZAP-70 (mouse monoclonal IgG2a, clone 2F3.2, Upstate Biotechnology, Lake Placid, NY) and then with a horseradish peroxidase-conjugated, antimouse secondary antibody (Bio-Rad). Subsequently, membranes were evaluated by chemiluminescence (Amersham Biosciences, Buckinghamshire, England).
Paraffin Immunohistochemical Analysis
Paraffin-embedded tissue samples fixed in formalin, B-5, or Hollande fixative were used for the study. Histologic slides were reviewed, and TMAs were constructed using 2 or 3 1.5-mm cores per case (Beecher Instruments, Sun Prairie, WI). Immunostaining was performed with automated immunostainers (Ventana Benchmark, Ventana Medical Systems, Tucson, AZ) using anti-ZAP-70 (clone 2F3.2, Upstate Biotechnology) at a dilution of 1:200. Heat-induced epitope retrieval was performed using CC2 solution (Ventana). A horseradish peroxidase-labeled streptavidinbiotin system with 3-3'-diaminobenzidine chromogen (Ventana) was used for localizing the anti-ZAP-70 antibody.
Samples tested included B-, T-, and NK-cell neoplasms; Hodgkin lymphomas; and acute myelogenous leukemias. The great majority of cases were evaluated by TMA; however, a small subset of cases was stained using whole sections. Positive staining was defined as greater than 10% lymphoma cell staining in which background small lymphocytes (T cells) were positive. The pattern of staining was cytoplasmic. In practice, the vast majority of tumor cells expressed ZAP-70 in the positive cases. Thus, there was no ambiguity due to a subset of neoplastic cells staining. In SLL cases, we noticed that the tumor cells often were of lesser intensity than normal T cells present in the biopsy specimen. Immunostaining in B-5 fixed and decalcified tissues can be done but is of lesser intensity than in formalin-fixed tissues in our hands and, therefore, is suboptimal.
Polymerase Chain Reaction
Polymerase chain reaction (PCR) was performed using primers for each leader sequence of the V H 1 to V H 6 families 13 and joining region primer. 14 PCR 1× buffer (PE Applied Biosystems, Foster City, CA); a 1.5-mmol/L concentration of magnesium chloride; 20 pmol of each primer; a 200-mmol/L concentration each of deoxyadenosine triphosphate, deoxycytidine triphosphate, deoxyguanosine triphosphate, and deoxythymidine triphosphate; and 2.5 U of AmpliTaq Gold DNA polymerase (Perkin-Elmer, Boston, MA) were combined for a total of 50 µL. Amplification consisted of an initial denaturation step of 10 minutes' duration followed by 35 cycles at 94°C, 55°C, and 72°C for 45 seconds each with a final extension of 10 minutes. The PCR products were spin-column purified (Qiagen, Valencia, CA) and then sequenced using the BigDye terminator V.3.1 cycle sequence kit (PE Applied Biosystems) and an automated sequencer (ABI 3100, PE Applied Biosystems). The V H , D, and J H sequences were analyzed and compared with the nearest germline sequences in the V Base database using DNAPLOT software (available from http://www.mrccpe.cam.ac.uk).
Results
To confirm that the monoclonal antibody indeed recognized ZAP-70, we performed Western blot analysis on a whole cell lysate of Jurkat cells (T-lymphoblastic cell line). This confirmed the presence of a strong 70-kd protein as shown in ❚Image 1❚. Epidermal growth factor-stimulated A431 carcinoma cells were used as the negative control, and the result was negative. Immunohistochemical analysis in normal tonsil confirmed a T-cell pattern with strong cytoplasmic immunoreactivity in the paracortical regions and negative secondary germinal centers ❚Image 2❚. Rare positive cells were present in the germinal centers, consistent with intrafollicular T cells. Having confirmed specificity and immunoreactivity in paraffin sections, we proceeded to screen cases of lymphoma and leukemia for ZAP-70 expression. Of the 446 cases of hematopoietic malignant neoplasms, 16.1% showed cytoplasmic staining for ZAP-70. The great majority of tumor cells were found to be positive when the case was positive (Image 2). Results are summarized in ❚Table 1❚. ZAP-70 was found in 45 (73%) of 62 cases of T-cell malignant neoplasms, 24 (11.7%) of 205 cases of B-cell malignant neoplasms, and 0 (0%) of 41 cases of acute myelogenous leukemia. One case of mixed-lineage B-and T-cell acute lymphoblastic leukemia was negative. One case of NK cell leukemia was positive for ZAP-70.
Of the T-cell malignant neoplasms, ZAP-70 was expressed in 40 (74%) of 54 peripheral T-cell lymphomas, unspecified; 4 (57%) of 7 T-cell acute lymphoblastic leukemias/lymphoblastic lymphomas; and 1 (100%) of 1 case of T-cell anaplastic large cell lymphoma. Of the B-cell malignant neoplasms, ZAP-70 was expressed in 12 (46%) of 26 small lymphocytic lymphomas, 4 (5%) of 76 diffuse large B-cell lymphomas (DLBCLs), 1 (17%) of 6 mantle cell lymphomas (MCLs), and 7 (29%) of 24 B-cell acute lymphoblastic leukemias/lymphoblastic lymphomas. B-cell malignant neoplasms that did not express ZAP-70 included marginal zone lymphoma (22 cases), follicular lymphoma (40 cases), Burkitt lymphoma (6 cases), and lymphoplasmacytic lymphoma (5 cases). Only 2 (1.5%) of 136 classic Hodgkin lymphoma cases showed Hodgkin cell staining.
Among the different positive neoplasms, we noticed in particular that SLL cases showed a distinct bimodal staining pattern with strong staining of scattered lymphocytes (likely T cells) and weaker staining of the lymphoma cells. This parallels our findings of ZAP-70 expression in CLL by flow cytometry, in which T cells and NK cells have higher levels ❚Image 2❚ G, Acute myeloid leukemia (negative) (×1,000). H, Precursor B lymphoblastic leukemia (positive) (×1,000). I, Hodgkin lymphoma (Reed-Sternberg cells negative) (×1,000).
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of ZAP-70 than neoplastic B cells (E.D.H., personal observation). Representative cases are shown in Image 2. Because ZAP-70 is being used as a surrogate for IGH mutational status, we sequenced 4 SLL cases to determine whether mutational status correlated with immunostaining pattern. As expected, 3 ZAP-70+ cases showed unmutated IGH (all >99.7% homology to germline sequences V3-23, V1-69, and V1-69), and 1 ZAP-70-case showed mutated IGH (87.6% homology to V4-34 ).
Discussion
ZAP-70, a Syk-family protein tyrosine kinase normally found in T cells, is an important signal transduction molecule that seems to be critical for TCR tyrosine phosphorylation pathways. It serves as a signal amplification molecule, and ZAP-70, through its interactions with LAT, can activate numerous important cell-signaling cascades. 4, 7 Interest in this molecule in hematologic malignancy has been fueled by the discovery that ZAP-70 is expressed in a subset of cases of CLL and that its expression by flow cytometry correlates well with IGH mutational status and poor outcome. 12 While major progress has been made in characterizing its expression in CLL, little is known about its expression in other hematologic malignant neoplasms, particularly in other Bcell lymphomas. Therefore, we undertook these immunohistochemical studies using TMAs to rapidly characterize ZAP-70 expression in a range of hematologic malignant neoplasms, including acute leukemias.
As expected, the majority of T-cell lymphomas expressed ZAP-70; 12 of 26 SLL/CLL cases expressed ZAP-70. Although it cannot be generalized as to overall expression of ZAP-70 in NK-cell lymphomas, it is interesting that in the 1 case tested, it was positive. Our findings in SLL are consistent with the published literature for CLL 11, 12 and confirm that immunohistochemical analysis can be used to detect the presence of ZAP-70 in fixed tissue samples. Furthermore, as recently reported in abstract form 15 and confirmed in a small number of SLL cases in our study, immunostaining for ZAP-70 seems to also correlate with mutational status of IGH.
The data in the present study also show that a small percentage of DLBCLs and MCLs also express ZAP-70, although the vast majority of mature B-cell neoplasms do not express ZAP-70 in immunohistochemical analysis. Rare cases of classic Hodgkin lymphoma show expression of ZAP-70 in Reed-Sternberg cells. Many precursor T-and Bcell neoplasms also express ZAP-70. Because pre-B cells in animal models seem to require ZAP-70 expression during Bcell development, 10 the presence of ZAP-70 in precursor Bcell neoplasms might not be so surprising.
In T-cell malignant neoplasms, it is presumed that the function of ZAP-70 is similar to that seen in normal T cells. However, the presence of ZAP-70 in mature B-cell malignant neoplasms is unexpected, and its function in this setting is uncertain. Because ZAP-70 is expressed in immature B cells in the bone marrow of mice, 10 it is possible that Syk and ZAP-70 might have at least partially redundant tyrosine kinase activity. Deficiency of Syk in developing B cells results in a marked but partial block in the maturation of pro-B to pre-B cells. 10, 16, 17 However, when Syk-deficient cells also are made ZAP-70-deficient, there is a complete block in the transition of B cells at the pro-B to pre-B stage that seems due to a lack of signaling through the pre-B-cell receptor. 10 Furthermore, other pre-B-cell receptor-induced cellular events also are abrogated, including loss of the normal allelic exclusion of heavy chains in a subset of cells. 10 Thus, ZAP-70 seems to have a function in precursor B cells, and one might argue that expression in precursor Bcell neoplasms reflects the normal expression pattern. However, this does not explain its presence at high levels in some mature B-cell neoplasms.
Although little is known about the function of ZAP-70 in human mature B-cell leukemia cells, we know that the molecule is functional. Chen and colleagues 18 recently have shown that activation of the B-cell antigen receptor in CLL cells expressing ZAP-70 results in greater tyrosine phosphorylation of cellular substrates than in CLL cells that lack ZAP-70 and that ZAP-70 itself also is tyrosine-phosphorylated. This latter point indicates that the kinase likely is active. It might be that an increase in signaling is related to the more aggressive clinical course in ZAP-70-expressing CLL cases. Whether a similar mechanism is active in other ZAP-70+ B-cell malignant neoplasms remains to be studied. We find it interesting that a subset of MCL cases also express ZAP-70, because a subset of MCLs also show IGH somatic mutations. 19 The significance is unknown because ZAP-70 expression in MCL evaluated by reverse transcriptase-PCR is not necessarily associated with mutational status. 20 However, only a minority of cases express ZAP-70, and only a minority of cases seem to have somatic hypermutation of IGH.
We have described the expression pattern of ZAP-70 in a series of B-and T-cell lymphomas and acute myeloid and lymphoblastic leukemias. As expected, ZAP-70 is expressed in the majority of T-cell malignant neoplasms and in a subset of SLLs. The percentage of cases of SLL that expressed ZAP-70 is consistent with the literature on CLL. Thus, immunohistochemical analysis might be an alternative to flow cytometric detection of ZAP-70 in CLL/SLL, although its usefulness in decalcified and B-5 fixed specimens has been shown to be limited. 15 We also showed expression in Bprecursor lymphoblastic leukemias/lymphomas, which might reflect normal expression patterns of ZAP-70. Myeloid leukemias lacked appreciable expression of ZAP-70. A minority of MCLs and DLBCLs and rare cases of classic Hodgkin lymphoma also expressed ZAP-70. The clinical significance of ZAP-70 expression in these cases is uncertain at this time.
